Dr Reddy’s Q2 numbers in line with estimates
Dr Reddy’s has come out with a decent set of numbers on revenue, EBITDA and profitability fronts, says Nikhil Shetty.
What is expense ratio in mutual fund investments and how often does it get deducted?
A mutual fund does not deduct the expense ratio all at o...
Hetero launches Favipiravir in India under the brand ‘Favivir’ to treat Covid-19
This is the second drug developed by Hetero after Covifor, t...
Dr Reddy's completes the acquisition of Wockhardt's select generics, plant
G V Prasad, Co-Chairman and Managing Director of Dr. Reddys said this deal is in line with the companys strategic focus on India and has paved a path for accelerated growthand leadership in the domestic market.
Hold Alkem Laboratories, target price Rs 2,616: Indsec
Alkem is now leveraging its existing network and has entered into the high margin chronic segment.
Is specialty business ‘a go or a no-go’ segment for pharma companies?
Leading pharma companies invested in specialty business to create a long-term growth driver.
True North to acquire 2.4% stake in Biocon Biologics
Deal values Biocon Biologics at $3 billion
Biocon Biologics debuts in Asia IP Elite list
Biocon, the Bengaluru-headquartered bio-pharma firm and the parent company for Biocon Biologics, has has been recognised as the ASIA IP ELITE for the fourth year in a row. Biocon’s subsidiary received this award at the recently concluded IP Business Congress Asia in Tokyo, Japan. Biocon Biologics has a product pipeline of 28 molecules.
Orient Electric launches EyeLuv LED lights to address the impact of invisible flicker on human eyes
The new range which has flicker-control technology reduces the harmful invisible flicker present in LED light that causes various health complications.
Lee Fixel to leave Tiger Global, set to hunt alone in India and beyond
Lee Fixel was the most important investor in Flipkart, working through close aide Kalyan Krishnamurthy.
Local pharma formulators to benefit from new USFDA generic guidance: Report
This will help domestic pharma formulators with pending ANDA approvals to reduce review cycles and expedite approvals, says a weekend report by India Ratings.
Eris Lifesciences, Shasun Strides shares rise on Rs 500 crore deal
The India branded generics business being divested by Strides had sales of Rs 181 core FY 2017, the statement said.
Eris signs definitive pact to buy Strides’ India portfolio for Rs 500 cr
The acquisition is Eris’s fourth and the largest buyout in the last 18 months. With this, the company will be among the top ten companies in the Central Nervous System (CNS) segment.
Dr Reddy’s agrees to buy UCB business in India for Rs 800 crore
The deal will help Dr Reddy's strengthen its presence in dermatology, pediatrics and respiratory products, the company said in a statement to the Bombay Stock Exchange.
Biogen to bring its global drug portfolio to India
US-based Biogen Idec plans to roll out its entire range of medicines in the fast-growing, Rs 40,000-crore Indian retail drug market over the next few years through its wholly-owned Indian arm.